Atara Biotherapeutics, Inc. (LON:0HIY)
17.81
+2.80 (18.69%)
Jan 9, 2026, 6:00 AM GMT
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $3.45M USD in the quarter ending September 30, 2025, a decrease of -91.41%. This brings the company's revenue in the last twelve months to $151.93M, up 51.27% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$151.93M
Revenue Growth
+51.27%
P/S Ratio
0.83
Revenue / Employee
$993.01K
Employees
153
Market Cap
93.62M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Atara Biotherapeutics News
- 20 days ago - Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canaccord Genuity | ATRA Stock News - GuruFocus
- 5 weeks ago - Atara Biotherapeutics: An Empty Pipeline With Little Gas - Seeking Alpha
- 2 months ago - Atara Biotherapeutics (ATRA) Reduces Workforce by 29% in Strategic Move - GuruFocus
- 2 months ago - Atara Biotherapeutics (ATRA) Exceeds Q3 Revenue Estimates - GuruFocus
- 2 months ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 2 months ago - Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Nasdaq
- 2 months ago - Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pierre Fabre - GuruFocus
- 2 months ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire